Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab

作     者：Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill 

作者机构：Macarthur Cancer Therapy CentreCampbelltownNSW 2560Australia NHMRC Clinical Trials CentreCamperdownNSW 2050Australia Department of Medical OncologyRoyal Melbourne HospitalParkvilleVIC 3052Australia Melbourne Medical SchoolUniversity of MelbourneMelbourneVIC 3000Australia Department of Medical OncologyBox Hill HospitalBox HillVIC 3128Australia St George Cancer Care CentreKogarahNSW 2217Australia Department of Medical OncologyWestern HospitalFootscrayVIC 3011Australia Department of Medical OncologyCabrini HealthMelbourneVIC 3000Australia Department of Medical Oncologythe Canberra HospitalGarranACT 2605Australia ANU Medical SchoolAustralia National UniversityCanberraACT 2600Australia Department of Medical OncologyRoyal Hobart HospitalHobartTAS 7000Australia Liverpool Cancer Therapy CentreLiverpoolNSW 2170Australia Department of Medical Oncologythe Queen Elizabeth HospitalWoodvilleSA 5011Australia Department of Medical OncologyAustin HealthHeidelbergVIC 3084Australia the Kinghorn Cancer CentreGarvan Institute of Medical ResearchDarlinghurstNSW 2010Australia 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第17期

页      面：5352-5358页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：the National Health and Medical Research Council Clinical Trials Centre were received from Cancer Australia and the Cancer Institute New South Wales for the AGITG MAX Trial 

主　　题：Peritoneal neoplasms Colorectal neoplasms Bevacizumab Intestinal perforation Capecitabine 

摘      要：AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal ***:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal *** endpoints included progression-free survival,chemotherapy duration,and overall ***-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank ***:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal *** were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC *** the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone *** the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone *** a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal p